In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles.

By Sai T. Reddy, A. Rehor, H. Schmoekel, J. Hubbell, M. Swartz. Journal of Controlled Release, 2006

653 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Interstitial flow and its effects in soft tissues. (2007, background): “Beyond a certain size, however, steric hindrance of proteins or particles can eventually cause complete entrapped in the matrix (83, 85, 86), an important limitation in the construction of microcarrier-based drug delivery therapies.”
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns (2010, background): “Molecules of 20–200 nm efficiently enter the lymphatic system, with an optimal size being ∼40 n”
Control of Polymeric Nanoparticle Size to Improve Therapeutic Delivery (2015, background): “Moreover, intradermally injected 20-nm pluronic-stabilized polypropylene sulfide (PPS) NPs traveled more efficiently through the interstitium to murine dLNs, and were retained longer than 45- and 100-nm NPs [90, 91], whereas the 100-nm NPs did not travel far from the injection site.”
Exploiting lymphatic transport and complement activation in nanoparticle vaccines (2007, background): “In previous work, size was shown to be the most critical factor affecting lymphatic uptake of particle-based delivery vehicle”